The Human Variable 

The Diagnostic Acceleration Blueprint™ modernizes IACC diagnostics by combining reuse-first biospecimen pipelines, digital consent, and ML-driven multi-system fingerprints. This framework cuts timelines by 95%, costs by 99%, and eliminates multi-year delays rooted in outdated systems.

CDF-POTS is a new AI powered diagnostic fingerprint that captures the hidden patterns of POTS across cognitive, cardiac, vascular, and orthostatic domains. An estimated 16.5M Americans are living with POTS, most without a formal diagnosis. This model removes diagnostic waste by 86 percent, cuts ER visits by 70 percent, and restores workforce participation while saving the United States up to 400B dollars annually.

Climate change is accelerating fungal evolution at the same moment millions of Americans are living with post-COVID immune instability. This white paper introduces CYNAERA’s national fungal-intelligence architecture, integrating climate analytics, immune-terrain modeling, wastewater genomics, micro-clinic stabilization, and antifungal combination logic. It explains why fungal threats are rising, how existing federal infrastructure can be repurposed immediately and what the Un

Chronic, multisystem collapse following infectious, environmental, or immunological insult has become one of the defining biomedical failures of the twenty-first century. The Unified Network Collapse Theory (UNCT™) reframes ME/CFS, Long COVID, POTS, MCAS, autoimmune destabilization, and post-vaccination or post-surgical syndromes as diversified expressions of a single systems-failure mode: Neuro-Immune-Autonomic Network Collapse. This framework is supported by decades of frag

When the full IACC population is included, the national total of adults likely experiencing medical sabotage, partner interference, or care-linked neglect rises to approximately 24 million. RAVYNS™ is the first integrated system to transform partner interference and institutional neglect in chronic-illness care into an auditable public-health metric.

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.